MyJournals.org - Science - Discordance of global assessment between the patients and physicians predicts 9-year pain-related outcomes in rheumatoid arthritis patients (Frontiers in Medicine)
FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug s clinical benefit for patients with Alzheimer s disease.
Blueprint Medicines (BPMC) Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group,.
Study aimed to determine the health-related quality of life (HRQoL) of COVID-19 patients after hospitalization. The study found that HRQoL is limited in COVID-19 ICU patients 3- and 12-months post COVID-19 hospitalization, with significantly less improvement at 12-months compared to non-ICU patients. Mental disorders were common, highlighting the complexity of post-COVID-19 symptoms.